Mayo Clinic Laboratory and Pathology Research Roundup: Dec. 19

By Kelley Luedke • December 19, 2016

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Development of a Microscopic Colitis Disease Activity Index

Microscopic colitis (MC) is a common cause of chronic diarrhea, often with additional symptoms. No validated instruments exist to assess disease activity in MC, making it difficult to compare efficacy of treatments between clinical trials. Mayo Clinic researchers aimed to identify clinical features that independently predicted disease severity and create a Microscopic Colitis Disease Activity Index (MCDAI). Patients with MC were prospectively administered a survey assessing their GI symptoms and the IBD Questionnaire (IBDQ). A single investigator also scored a physician global assessment (PGA) of disease severity on a 10-point scale. These symptoms were then combined in a weighted formula to create the MCDAI. The MCDAI strongly predicted the PGA and correlated with a validated measure of quality of life. Several symptoms in addition to diarrhea are associated with disease severity in MC. The study was published in Gut.

Published to PubMed This Week

• WSB1 Overcomes Oncogene-Induced Senescence by Targeting ATM for Degradation
  Cell Research
• Staphylococcus epidermidis Small-Colony Variants Are Induced by Low pH and Their Frequency Reduced by Lysosomal Alkalinization
  Journal of Infectious Diseases
• The Value of Protocol Biopsies to Identify Patients with De Novo Donor Specific Antibody at High Risk for Allograft Loss
  American Journal of Transplantation
• Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
  Targeted Oncology
• Clinical Characteristics and Platelet Phenotype in a Family with RUNX1 Mutated Thrombocytopenia
  Leukemia Lymphoma
• Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era
  Annals of Thoracic Surgery
• Patient Factors Associated with 30-Day Complications After Partial Nephrectomy: A Contemporary Update
  Urologic Oncology
• Effect of Genetic Variants of Bilirubin Metabolism on the Degree of Hyperbilirubinemia in African-American Newborns
  Journal of Perinatology
• ACR Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer
  Brachytherapy

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.